Roche Joins Forces to Innovate Toxicity Testing and to Reduce Animal Experimentation
News May 19, 2009
Roche has opened the Joint Science & Technology Laboratory in Basel, where Roche Pharma scientists are using the xCELLigence real-time Cell Analyzer system of Roche Diagnostics to investigate hepatic and cardiac toxicities in vitro. This new technology will improve the predictive value of in vitro assessments of organ toxicity and help to reduce animal testing in toxicity research.
Cell-based in vitro assays are a key tool for early assessment of drug candidates. Toxicology routinely employs these assays, for example to determine genotoxicity. The non-clinical safety community is developing other assays especially for prediction of organ-specific toxicity.
“New techniques such as Real-time cell analysis with the xCELLigence system will accelerate the ability to identify the toxic potential of a compound at an early stage of drug development, which supports also Roche´s 3Rs concept of Reducing, Refining, and Replacing animal experimentation,” stated Thomas Singer, Head of Global Non-Clinical Safety at Roche Pharma.
“This project is yet another example for the advantage of having pharma and diagnostics under one roof,” added Manfred Baier, Head of Roche Applied Science. “We are in the process of identifying more and more opportunities in working together for more efficient processes and in the development of treatments that are tailor-made for the patients.”
The non-invasive and label-free xCELLigence technology is based on measuring the impedance of cells: The variations in electrical resistance are caused by changes in numbers, adhesion or shape of the cells. In conjunction with its user-friendly data collection and analysis capabilities, the xCELLigence system makes a platform for continuous, real-time cell-based assays and provides a huge opportunity for cellular and molecular biology.
The data from the xCELLigence real-time impedance measurement, combined with molecular profiling of the toxic effects of compounds on cardiomyocytes and hepatocytes, will be compared to conventional cell biology assays and molecular endpoints. Based on this platform, the goal is to develop new prediction methods for target organ toxicity in vitro and identify new cellular biomarkers for toxicity prediction.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.